AIFA has approved Elacestrant, an innovative oral therapy produced in Pisa which blocks the progression of breast cancer metastases
A new hope in the fight against metastatic breast cancer comes from Italy. AIFA (Italian drug agency) has in fact Elacestrant approvedone Innovative oral therapy Able to block the progression of cancer in patients who no longer respond to first -line treatments. The molecule, already on the market in United States, Germany and the United Kingdomwill also be available in Italy within three monthsand will be produced in the establishment of the Menarini in Pisa.
Also known by the commercial name of Orserdu, Elacestrant represents an important milestone in the treatment of advanced forms of breast cancer. It is not a drug that leads to healing, but which is able to significantly slow down the disease“Freezing” the metastases and improving the quality of life of patients.
Your strong point? AND administered orallyeliminating the need for invasive treatments such as chemotherapy. The elacestrant action mechanism is particularly effective in patients who have developed one Estectogen receptor mutationresponsible for the resistance to many therapies. This drug binds to the changed receptor and induces degradationthus contrasting the proliferation of tumor cells.
Two compounds against solid tumors in development
The Pisan Center of Menarini, specialized in the creation of high therapeutic potential molecules, does not stop there. Are in the initial development phase Two new compounds destined to fight solid tumorsdesigned thanks to the use ofartificial intelligence. This technology, increasingly present in research, allows you to identify promising molecules to be tested in the laboratory in reduced times.
According to experts, Elacestrant could become a therapeutic pillar in oncology. It is currently accessible only for exceptional cases through compassionate use, but soon it will be integral part of standard therapy For many patients. Italian approval also marks a Success for the Tuscan pharmaceutical industrycapable of combining innovation, production and research in a single supply chain.
With about One in eight women hit by breast cancer during life and a not negligible percentage of diagnosis already in the metastatic phase, Elacestrant represents an important step forward towards more targeted therapies e less invasive.
